BACKGROUND: In clinical stage IIIA non-small cell lung cancer, the role of surgical resection, particularly pneumonectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of survival after postinduction surgical resection. METHODS: We retrospectively reviewed a prospectively collected database of 136 patients who underwent surgical resection after induction chemotherapy (n = 119) or chemoradiation (n = 17) from June 1990 to January 2010. RESULTS: One hundred five lobectomies or bilobectomies and 31 pneumonectomies were performed. There was 1 perioperative death (pneumonectomy). Seventy-one patients had downstaging to N0 or N1 nodal status (52%). There were 2 complete pathologic responses. Median follow-up was 42 months (range, 0.69-136 months). Overall 5-year survival for entire cohort was 33% (36% lobectomy, 22% pneumonectomy, P = .001). Patients with pathologic downstaging to pN0 or pN1 had improved 5-year survival (45% vs 20%, P = .003). For patients with pN0 or pN1 disease, survival after lobectomy was better than after pneumonectomy (48% vs 27%, P = .011). In patients with residual N2 disease, there was no statistically significant survival difference between lobectomy and pneumonectomy (5-year survival, 21% vs 19%; P = .136). Multivariate analysis showed as independent predictors of survival age (hazard ratio, 1.05; P = .002), extent of resection (hazard ratio, 2.01; P = .026), and presence of residual pN2 (hazard ratio, 1.60; P = .047). CONCLUSIONS: After induction therapy for patients with clinical stage IIIA disease, both pneumonectomy and lobectomy can be safely performed. Although survival after lobectomy is better, long-term survival can be accomplished after pneumonectomy for appropriately selected patients. Nodal downstaging is important determinant of survival, particularly after lobectomy.
BACKGROUND: In clinical stage IIIA non-small cell lung cancer, the role of surgical resection, particularly pneumonectomy, after induction therapy remains controversial. Our objective was to determine factors predictive of survival after postinduction surgical resection. METHODS: We retrospectively reviewed a prospectively collected database of 136 patients who underwent surgical resection after induction chemotherapy (n = 119) or chemoradiation (n = 17) from June 1990 to January 2010. RESULTS: One hundred five lobectomies or bilobectomies and 31 pneumonectomies were performed. There was 1 perioperative death (pneumonectomy). Seventy-one patients had downstaging to N0 or N1 nodal status (52%). There were 2 complete pathologic responses. Median follow-up was 42 months (range, 0.69-136 months). Overall 5-year survival for entire cohort was 33% (36% lobectomy, 22% pneumonectomy, P = .001). Patients with pathologic downstaging to pN0 or pN1 had improved 5-year survival (45% vs 20%, P = .003). For patients with pN0 or pN1 disease, survival after lobectomy was better than after pneumonectomy (48% vs 27%, P = .011). In patients with residual N2 disease, there was no statistically significant survival difference between lobectomy and pneumonectomy (5-year survival, 21% vs 19%; P = .136). Multivariate analysis showed as independent predictors of survival age (hazard ratio, 1.05; P = .002), extent of resection (hazard ratio, 2.01; P = .026), and presence of residual pN2 (hazard ratio, 1.60; P = .047). CONCLUSIONS: After induction therapy for patients with clinical stage IIIA disease, both pneumonectomy and lobectomy can be safely performed. Although survival after lobectomy is better, long-term survival can be accomplished after pneumonectomy for appropriately selected patients. Nodal downstaging is important determinant of survival, particularly after lobectomy.
Authors: Chi-Fu Jeffrey Yang; Robert Ryan Meyerhoff; Nicholas Ryan Mayne; Terry Singhapricha; Christopher B Toomey; Paul J Speicher; Matthew G Hartwig; Betty C Tong; Mark W Onaitis; David H Harpole; Thomas A D'Amico; Mark F Berry Journal: Eur J Cardiothorac Surg Date: 2015-12-30 Impact factor: 4.191
Authors: Asad A Shah; Mathias Worni; Christopher R Kelsey; Mark W Onaitis; Thomas A D'Amico; Mark F Berry Journal: Ann Thorac Surg Date: 2013-03-29 Impact factor: 4.330
Authors: R Taylor Ripley; Kei Suzuki; Kay See Tan; Prasad S Adusumilli; James Huang; Bernard J Park; Robert J Downey; Nabil P Rizk; Valerie W Rusch; Manjit Bains; David R Jones Journal: J Thorac Cardiovasc Surg Date: 2015-10-19 Impact factor: 5.209
Authors: Pamela Samson; Aalok Patel; Traves D Crabtree; Daniel Morgensztern; Cliff G Robinson; Graham A Colditz; Saiama Waqar; Daniel Kreisel; A Sasha Krupnick; G Alexander Patterson; Stephen Broderick; Bryan F Meyers; Varun Puri Journal: Ann Thorac Surg Date: 2015-07-28 Impact factor: 4.330
Authors: Sibu P Saha; Rohan J Kalathiya; Daniel L Davenport; Victor A Ferraris; Timothy W Mullett; Joseph B Zwischenberger Journal: Oman Med J Date: 2014-01